ClinPhone, a Clinical Technology Organization (CTO) and Cytel Inc., statistical experts in adaptive clinical trials, announced a partnership that unites expertise and clinical technologies
ClinPhone and Cytel – A New Partnership Delivering Complete Solutions for Adaptive Clinical Trials
(Nottingham, UK and Cambridge, USA 2 July 2008). ClinPhone, the world’s largest Clinical Technology Organization (CTO) and Cytel Inc., leading statistical experts in adaptive clinical trials, announced today a unique partnership that unites Cytel’s validated adaptive trial statistical and computational expertise with ClinPhone’s robust suite of clinical technologies and operational know-how.
This new partnership offers sponsors the combined expertise of the two organizations in successful design, planning and implementation of adaptive and other complex study designs. ClinPhone-Cytel adaptive trial solutions are tailored to the requirements and objectives of each individual clinical development program. This integrated service provides all the essential components for adaptive trial planning and implementation, including study design consulting, trial simulations, supplies planning and management, clinical data collection, randomization, trial supply management, data analysis and reporting.
Adaptive Clinical Trials (ACTs) refer to clinical studies that use accumulating response data to optimize pre-determined aspects of the study design without undermining the validity and integrity of the trial. By making mid-course adjustments to the trial, adaptive trials increase the ability to answer the study’s key research objectives, and improve the likelihood of a successful outcome. ClinPhone-Cytel solutions combine the innovative statistical techniques and trial technology advances that make designing and conducting adaptive trials practical for sponsor organizations of all sizes.
Irving Dark, Cytel’s Vice President of Clinical Research Services explains, “The ClinPhone-Cytel collaboration provides sponsors with the full-service offering needed for successful Adaptive Clinical Trials. This partnership underscores our commitment to be the leader in innovative trial design and implementation services.”
Dr. Bill Byrom, Vice President, Product Strategy and Marketing of ClinPhone comments, “Technology plays a central role in delivering these types of studies, and Cytel and ClinPhone together are leading the way in offering integrated services that provide a comprehensive solution for the sponsor wishing to benefit from the power of adaptive trials.”
To learn more about ClinPhone’s clinical trial technology solutions, please visit www.clinphone.com, or alternatively e-mail [email protected].
To learn more about Cytel Inc, please visit www.cytel.com, or alternatively e-mail [email protected].
About ClinPhone
ClinPhone plc is the world’s largest Clinical Technology Organization (CTO) with an unrivaled track record of innovation in the development of clinical trial technology. Headquartered in Nottingham UK with offices around the world, ClinPhone works with leading global biotechnology organizations, pharmaceutical companies and Contract Research Organizations (CROs).
ClinPhone is the largest and most accomplished CTO with experience in over 2,000 clinical trials spanning 88 countries and 71 languages. The Company’s experience includes Phase I to Phase IV studies, ranging from single center studies with 20 patients to “mega trials” with over 40,000 patients.
ClinPhone’s product portfolio, consisting of software and services, is backed by continuous research and investment in the latest technologies, coupled with extensive in-depth clinical industry experience. Its industry-leading software solutions include electronic data capture (EDC) and clinical trial management systems (CTMS), which can be licensed or implemented as hosted solutions. Delivered via its renowned Interactive Voice Response (IVR) and Interactive Web Response (IWR) platform, ClinPhone offers randomization, trial supply management, trial supply simulation, electronic patient reported outcomes (ePRO), and patient recruitment solutions.
ClinPhone’s products can integrate, taking the pain out of juggling and managing multiple sources of disparate information. This approach provides more control over data, improves data integrity and streamlines the data validation process.
About Cytel
Cytel pioneered the statistical science and computational technology of adaptive clinical trials. Benefiting both sponsors and patients, Cytel has designed more validated adaptive trials than anyone else.
Biopharmaceutical and device companies of all sizes turn to the clinical study planning, simulation and implementation experience of Cytel. Cytel experts have trained thousands of health sciences industry biostatisticians, clinicians, and regulatory staff in the latest trial design techniques.
Cytel’s Pharmaceutical Research Services place this clinical study innovation experience at the disposal of your research and development programs. From trial simulation and process development to independent data assessment and regulatory review, Cytel stands with you every step of the way.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.